Trial · NCT04926233
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | At index date of cohort entry (baseline; time of COPD diagnosis). | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). |
| Primary | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | At index date of cohort entry (baseline; time of COPD diagnosis). | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). |
| Primary | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | At index date of cohort entry (baseline; time of COPD diagnosis). | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Primary | Age of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported. |
| Primary | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Primary | Characteristics of Patients Receiving First Maintenance Treatment - US | At index date of the first maintenance treatment | Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported. |
| Primary | Age of Patients Receiving First Maintenance Treatment - UK | At index date of the first maintenance treatment | Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Primary | Characteristics of Patients Receiving First Maintenance Treatment - UK | At index date of the first maintenance treatment | Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Primary | Age of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported. |
| Primary | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Primary | Characteristics of Patients Receiving Second Maintenance Treatment - US | At index date of the second maintenance treatment | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported. |
| Primary | Age of Patients Receiving Second Maintenance Treatment - UK | At index date of the second maintenance treatment | Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Primary | Characteristics of Patients Receiving Second Maintenance Treatment - UK | At index date of the second maintenance treatment | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | At index date of the first maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. |
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | At index date of the first maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | At index date of the second maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported. |
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | At index date of the second maintenance treatment | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. |
| Secondary | Days Between Index and Initiation of First Maintenance Therapy - US | From index date until initiation of first maintenance, up to 3368 days before this study started. | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. |
| Secondary | Days Between Index and Initiation of First Maintenance Therapy - UK | From index date until initiation of first maintenance therapy, up to 9795 days before this study started. | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. |
| Secondary | Days Between First and Second Maintenance Therapy - US | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started. | Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04926233/registered